 Linezolid 's spectrum of activity against Gram @-@ positive bacteria is similar to that of the glycopeptide antibiotic vancomycin , which has long been the standard for treatment of MRSA infections , and the two drugs are often compared . Other comparable antibiotics include teicoplanin ( trade name <unk> , a glycopeptide like vancomycin ) , <unk> / <unk> ( <unk> , a combination of two <unk> , not active against E. faecalis ) , and <unk> ( <unk> , a <unk> ) , and some agents still being developed , such as <unk> , <unk> , and <unk> . Linezolid is the only one that can be taken by mouth . In the future , <unk> and <unk> may be useful oral alternatives to linezolid — both are in the early stages of clinical development . 
